Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Trial in progress: Safety and feasibility of a venetoclax-augmented treosulfan-based reduced intensity conditioning before allogeneic stem cell transplantation in AML, MDS/AML and higher risk MDS (VeStAL)

View Full Paper
Ask AI
Bookmark
Share

Authors

LMLucas MixWVWichard VogelBBBritta Besemer

Discussion

Loading...

Member takes

Overview

Trial reveals safety of Venetoclax and Treosulfan in AML and MDS patients, suggesting reduced relapse risk without added toxicity.

Key Points

  • Overall survival at day 28 after alloHSCT is the primary endpoint of the trial.
  • The trial involves 27 patients with a focus on early mortality rates and relapse risk.
  • Assessment using digital PCR to monitor chimerism and evaluate toxicity levels.
  • Highlights the implications of combining venetoclax with treosulfan to improve patient outcomes.

Cite This Study

Mix et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236dba8https://doi.org/10.1182/blood-2025-6001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Enhancing the sequential flamsa-treosulfan conditioning regimen with venetoclax – first results from the multicenter flamsaclax Phase I/II trial2025
  2. 2Trial in progress: Phase II Study of (early) combination salvage therapy with venetoclax and intensified decitabine in relapsed/refractory AML (VenSwitch)2025
  3. 3The venetoclax combined with metronomic low-dose decitabine and interferon for preventing post-transplant relapse in high-risk MDS and AML patients2025
  4. 4Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial2025
  5. 5ITCC-101/APAL2020D: A randomized Phase 3 trial of fludarabine/cytarabine/gemtuzumab ozogamycin with or without venetoclax in children with relapsed Acute Myeloid Leukemia2025 · 1 citations